Results 151 to 160 of about 139,558 (270)

Cost-effectiveness of azithromycin for preventing Mycobacterium avium complex infection in HIV-positive patients in the era of highly active antiretroviral therapy [PDF]

open access: bronze, 1999
Peter P. Sendi   +7 more
openalex   +1 more source

Trend and Associated Factors for Late and Advanced HIV Diagnoses in 2011–2022 in Melbourne, Australia

open access: yesJournal of Medical Virology, Volume 97, Issue 6, June 2025.
ABSTRACT Late‐ and advanced HIV diagnoses remain significant challenges worldwide. Understanding the factors associated with and testing practice among those with late (CD4 < 350 cells/µL) and advanced diagnoses (CD4 < 200 cells/µL) is essential to diminish AIDS‐related morbidity and mortality.
Warittha Tieosapjaroen   +9 more
wiley   +1 more source

Critical Care Pharmacology of Antiretroviral Therapy in Adults. [PDF]

open access: yesEur J Drug Metab Pharmacokinet
La Via L   +9 more
europepmc   +1 more source

Saquinavir/zidovudine combination in patients with advanced HIV infection and no prior antiretroviral therapy: CD4 + lymphocyte/plasma RNA changes, and emergence of HIV strains with reduced phenotypic sensitivity [PDF]

open access: green, 1996
Stefano Vella   +8 more
openalex   +1 more source

Posttransplant EBV‐Positive Smooth Muscle Tumors in Children, Adolescents, and Young Adults: A Multi‐Institution Experience

open access: yesPediatric Blood &Cancer, Volume 72, Issue 6, June 2025.
ABSTRACT Epstein–Barr virus (EBV)‐positive smooth muscle tumors (SMTs) are rare tumors seen in immunocompromised patients. There is no clear standard of care for the management and treatment of EBV‐SMTs. Patients are often treated with chemotherapy, surgery, and/or radiation.
Meghan Haney   +7 more
wiley   +1 more source

Resolution of Mycobacterium avium Complex Bacteremia Following Highly Active Antiretroviral Therapy [PDF]

open access: bronze, 1998
David Jamil Hadad   +5 more
openalex   +1 more source

Population pharmacokinetics and exposure‐response relationship for temsavir following fostemsavir administration in treatment‐experienced HIV patients

open access: yesPharmacology Research &Perspectives, Volume 13, Issue 3, June 2025.
The temsavir population PK model is a two‐compartment model with dual zero‐ and first‐order absorption and first‐order elimination. CL, apparent clearance; DUR, duration of zero‐order absorption process, Ka, first‐order absorption rate constant; Q, intercompartmental clearance; Vc, volume of distribution of central compartment; Vp, volume of ...
Ridhi Parasrampuria   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy